Atara Biotherapeutics Inc. has announced a new share issuance, involving the sale of 834,237 shares of its common stock at $6.61 per share, along with pre-funded warrants for an additional 1,587,108 shares priced at $6.6099 per share. This offering, primarily involving entities like Adiumentum Capital Management, EcoR1 Capital, Panacea Venture, and Redmile Group, is expected to generate gross proceeds of $16 million for Atara. The funds will be directed towards the company's efforts to achieve biologics license application approval for tab-cel and support general corporate expenses. The offering is anticipated to close on May 16, 2025, following the fulfillment of customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.